# Multinational randomised controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritis

Submission date Recruitment status Prospectively registered 09/05/2002 No longer recruiting [ ] Protocol [ ] Statistical analysis plan Overall study status Registration date 09/05/2002 Completed [X] Results [ ] Individual participant data Last Edited Condition category Musculoskeletal Diseases 15/11/2013

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Mr Sean Curtis

#### Contact details

Merck & Co Inc 126 E Lincoln Avenue Rahway United States of America NJ 07065

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

025

# Study information

#### Scientific Title

#### **Study objectives**

Not provided at time of registration

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Each site received the approval of its Ethics Review Committee or Institutional Review Board to perform the study.

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

# Participant information sheet

# Health condition(s) or problem(s) studied

Rheumatoid arthritis

#### **Interventions**

- 1. Etoricoxib 90 mg once daily, naproxen 500 mg twice daily
- 2. Placebo for 12 weeks

# Intervention Type

Drug

#### Phase

**Not Specified** 

# Drug/device/biological/vaccine name(s)

Etoricoxib, naproxen

#### Primary outcome measure

Not provided at time of registration

# Secondary outcome measures

Not provided at time of registration

# Overall study start date

01/11/1999

# Completion date

01/06/2000

# Eligibility

# Key inclusion criteria

- 1. Patients with rheumatoid arthritis
- 2. Aged greater than or equal to 18 years

## Participant type(s)

**Patient** 

#### Age group

Adult

#### Lower age limit

18 Years

#### Sex

Both

# Target number of participants

891

# Key exclusion criteria

Does not match inclusion criteria

# Date of first enrolment

01/11/1999

#### Date of final enrolment

01/06/2000

# Locations

# Countries of recruitment

Argentina

Australia

Austria

Brazil

Canada					
Chile					
Colombia					
Costa Rica					
France					
Germany					
Greece					
Hong Kong					
Israel					
Italy					
Lithuania					
Mexico					
New Zealand					
Peru					
Romania					
Singapore					
Slovenia					
South Africa					
Spain					
Switzerland					
Türkiye					
United Kingdom					
United States of America					
Venezuela					

# Study participating centre

#### Merck & Co Inc

Rahway United States of America NJ 07065

# Sponsor information

# Organisation

Merck & Co Inc (USA)

## Sponsor details

126 E Lincoln Avenue Rahway United States of America NJ 07065

#### Sponsor type

Industry

#### Website

http://www.merck.com

# Funder(s)

#### Funder type

Industry

#### Funder Name

Merck & Co Inc (USA)

#### Alternative Name(s)

Merck & Co., Inc., Merck & Co.

# **Funding Body Type**

Government organisation

# Funding Body Subtype

For-profit companies (industry)

#### Location

United States of America

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	22/05/2002		Yes	No